.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,536,155

« Back to Dashboard

Details for Patent: 8,536,155

Title:Process for preparing malathion for pharmaceutical use
Abstract: The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.
Inventor(s): Gutman; Daniella (Rishon Lezion, IL), Baidussi; Wael (Hamisholash, IL)
Assignee: Taro Pharmaceuticals North America, Inc. (Grand Cayman, KY)
Filing Date:Sep 22, 2011
Application Number:13/239,750
Claims:1. A topical pharmaceutical formulation comprising at least 70% (w/w) isopropyl alcohol, and terpineol, dipentene, pine needle oil, and pharmaceutical grade malathion, said pharmaceutical grade malathion containing 0.1% or less (w/w) MeOOSPO, 0.1% or less (w/w) MeOSSPO, 0.2% or less (w/w) MeOOSPS, less than 0.1% (w/w) methyl malathion, 0.1% or less (w/w) malaoxon and 0.1% or less (w/w) isomalathion.

2. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion has a purity greater than 98.5% (w/w).

3. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion has a purity of greater than 99% (w/w).

4. The topical pharmaceutical formulation of claim 1 wherein the pharmaceutical grade malathion contains 0.05% or less (w/w) MeOOSPO.

5. The topical pharmaceutical formulation of claim 1 wherein the pharmaceutical grade malathion contains 0.04% or less (w/w) MeOOSPO.

6. The topical pharmaceutical formulation of claim 1 wherein the pharmaceutical grade malathion contains 0.02% or less (w/w) MeOSSPO.

7. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains not more than about 0.1% (w/w) of any other detectable impurity.

8. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains 0.08% or less (w/w) methyl malathion.

9. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains 0.06% or less (w/w) methyl malathion.

10. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains 0.05% or less (w/w) isomalathion.

11. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains 0.02% or less (w/w) isomalathion.

12. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains 0.2% or less (w/w) diethyl fumarate and 0.2% or less (w/w) dimethylmalathion.

13. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains less than 0.05% (w/w) malaoxon.

14. The topical pharmaceutical formulation of claim 1 wherein the pharmaceutical grade malathion contains 0.1% or less (w/w) MeOOSPS.

15. The topical pharmaceutical formulation of claim 1, wherein the amount of isomalathion in the pharmaceutical grade malathion is not more than 0.1% (w/w), after storage for 3 months at 25.degree. C. and 60% relative humidity.

16. The topical pharmaceutical formulation of claim 1, comprising at least 0.5% (w/w) pharmaceutical grade malathion.

17. The topical pharmaceutical formulation of claim 1, comprising 0.65% (w/w) of the pharmaceutical grade malathion.

18. The topical pharmaceutical formulation of claim 1, wherein the pharmaceutical grade malathion contains less than 0.1% (w/w) MeOOSPO, less than 0.1% (w/w) MeOSSPO, and less than 0.1% malathion carboxylic acids.

19. The topical pharmaceutical formulation of claim 1, comprising at least 12% (w/w) terpineol, at least 10% (w/w) dipentene, and at least 0.28% (w/w) pine needle oil.

20. The topical pharmaceutical formulation of claim 1 wherein the formulation is a lotion.

21. The topical pharmaceutical formulation of claim 1 wherein the formulation is a gel.

22. The topical pharmaceutical formulation of claim 1 wherein the formulation is a cream.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc